Birk Venture: Pre-Seed to Seed

Investment focus

Investment stages

Geographic focus

Nordics

Inferred thesis

Auto-generated from public data. Not the firm's stated position.

Birk Venture appears to focus on early-stage biotech and healthtech companies, with particular emphasis on oncology and immunotherapy based on disclosed portfolio companies. Recent investment activity suggests a concentration in pre-seed and seed stage funding with check sizes ranging from €0.1M to €1.5M, primarily targeting companies developing novel therapeutic modalities.

Generated 14 Oct 2026 from disclosed sectors, stages, and portfolio companies. Is this your firm? Claim the profile to correct it.

How to Pitch Birk Venture

No stated policy
Birk Venture hasn't published an outreach policy. A short, specific cold email is the safest default.

Portfolio highlights

APIM Therapeutics - DNA repair drugs, Zelluna Immunotherapy - TCR immunotherapy, Accession Therapeutics - Cancer-tropic viruses

Focus and check size from the firm's website. Website reachable as of Sept 2026.

Ready to reach Birk Venture?

Red-pen your deck first so the gaps are fixed before they read it. A fit check then scores your pitch against their thesis, stage and ticket, and an email draft uses their real deals and thesis, not a template.

Contact

birkventure.no

Reach Birk Venture through the links above. Pitchkit is not affiliated with the firm and does not forward pitches.